Company Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial.
Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.
Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy.
Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jul 24, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5,400 |
| CEO | Dr. Reshma Kewalramani FASN, M.D. |
Contact Details
Address: 50 Northern Avenue Boston, Massachusetts 02210 United States | |
| Phone | (617) 341-6393 |
| Website | vrtx.com |
Stock Details
| Ticker Symbol | VRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875320 |
| CUSIP Number | 92532F100 |
| ISIN Number | US92532F1003 |
| Employer ID | 04-3039129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman |
| Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President and Director |
| Charles F. Wagner Jr. | Executive Vice President and Chief Financial Officer |
| Stuart A. Arbuckle B.Sc. | Executive Vice President and Chief Operating Officer |
| Dr. David M. Altshuler M.D., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Kristen C. Ambrose CPA | Senior Vice President and Chief Accounting Officer |
| Mike Tirozzi | SVice President and Chief Information and Data Officer |
| Susie Lisa | Senior Vice President of Investor Relations |
| Jonathan Biller J.D. | Executive Vice President and Chief Legal Officer |
| Nina Devlin | Senior Vice President and Chief Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Apr 11, 2024 | SC TO-C | Filing |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 4, 2024 | ARS | Filing |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 26, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |